ArticleJournal of clinical microbiology2003
In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes.
Article in Journal of clinical microbiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 43 citations in OpenAlex.
- Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Discovery of Anti-Amoebic Inhibitors from Screening the MMV Pandemic Response Box onPathogens (Basel, Switzerland) · 2020Article
- LowCurrent medical mycology · 2020Article
- 2-(benzylideneamino)phenol: a promising hydroxyaldimine with potent activity against dermatophytoses.Mycopathologia · 2015Article
- Anti dermatophytic therapy--prospects for the discovery of new drugs from natural products.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2013Review
- In-vitro Activity of 10 Antifungal Agents against 320 Dermatophyte Strains Using Microdilution Method in Tehran.Iranian journal of pharmaceutical research : IJPR · 2013Article
- Transcriptional profiles of the response to ketoconazole and amphotericin B in Trichophyton rubrum.Antimicrobial agents and chemotherapy · 2007Article
- In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases.Antimicrobial agents and chemotherapy · 2005Article
- Evaluation of disk diffusion method for determining eberconazole susceptibility of dermatophytes and influence of culture medium.Antimicrobial agents and chemotherapy · 2005Article
- Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT).Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have compared the in vitro activity of the new antifungal drug eberconazole with those of three other topical antifungal agents, clotrimazole, ketoconazole, and miconazole, against 200 strains of dermatophytes. MICs were determined by a microdilution method with optimal conditions determined in a previous study (an inoculum of 10(4) CFU/ml, an incubation temperature of 28 degrees C, an incubation period of 7 days, and a MIC endpoint of 100% inhibition of growth). In general, the four drugs tested showed low MICs. However, eberconazole was more active (P < 0.05) than the other three drugs against the majority of the species tested. Eberconazole represents an advantageous alternative for dermatophytoses where a topical therapy is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.